Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cancer drug bomedemstat tested for Long-Term safety

NCT ID NCT06351631

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 400 people with certain blood cancers (like essential thrombocythemia and myelofibrosis) who are already taking bomedemstat and benefiting from it. The goal is to collect more information on the drug's long-term safety and how well it controls the disease over time. Participants will continue taking bomedemstat capsules and be monitored for side effects and response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bomedemstat (oral capsules)
What this could lead to
If successful, this study could confirm that bomedemstat is safe and effective for long-term use in controlling certain blood cancers.
What could go wrong
This is an extension study with no hypothesis testing, so it won't prove the drug works. Side effects are possible, and results may not apply to new patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Dec 2034

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck \& Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready * Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator * ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic remission, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator * Is not currently on a dose hold * Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat Exclusion Criteria: * Has received prohibited concomitant medications * Ongoing or planned participation in another investigational study * Has noncompliance in prior bomedemstat study receiving \<90% of assigned doses excluding suspensions or holds as assigned by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myelofibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myelofibrosis Polycythemia vera Post-essential thrombocythemia myelofibrosis Post-polycythemia vera myelofibrosis Primary myelofibrosis Thrombocythemia essential

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    18 sites in 4 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Aotearoa Clinical Trials ( Site 1400)

    ACTIVE_NOT_RECRUITING

    Auckland, 2025, New Zealand

  • Azienda Ospedaliera Universitaria Careggi ( Site 2700)

    RECRUITING

    Florence, Tuscany, 50134, Italy

  • Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703)

    RECRUITING

    Alessandria, 15121, Italy

  • Boston Pilgrim Hospital ( Site 3403)

    RECRUITING

    Boston, Lincolnshire, PE21 9QS, United Kingdom

  • DUHS Duke Blood Cancer Center ( Site 6005)

    RECRUITING

    Durham, North Carolina, 27705, United States

  • Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002)

    RECRUITING

    Southport, Queensland, 4215, Australia

  • Guy's & St Thomas' NHS Foundation Trust ( Site 3401)

    RECRUITING

    London, London, City of, SE1 9RT, United Kingdom

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702)

    RECRUITING

    Bologna, 40138, Italy

  • Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)

    RECRUITING

    London, Hammersmith and Fulham, W12 0HS, United Kingdom

  • Monash Health ( Site 1004)

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • North Shore Hospital-Department of Haematology ( Site 1401)

    ACTIVE_NOT_RECRUITING

    Auckland, 0622, New Zealand

  • Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701)

    RECRUITING

    Varese, 21100, Italy

  • Queen Mary Hospital ( Site 1601)

    ACTIVE_NOT_RECRUITING

    Hksar, Hong Kong

  • Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000)

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Royal North Shore Hospital ( Site 1001)

    RECRUITING

    St Leonards, New South Wales, 2065, Australia

  • Royal Prince Alfred Hospital ( Site 1003)

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Sunshine Coast Hematology and Oncology Clinic ( Site 1006)

    RECRUITING

    Buderim, Queensland, 4556, Australia

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)

    RECRUITING

    Columbus, Ohio, 43210, United States

  • UPMC Hillman Cancer Center ( Site 6004)

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • University College London Hospital ( Site 3400)

    RECRUITING

    London, London, City of, NW1 2PG, United Kingdom

  • University of Michigan ( Site 6000)

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.